The Day In Review: Pfizer Inc. Anti-Smoking Drug Chantix Gets Approved

Published: May 11, 2006

May 11, 2006 – Pfizer received FDA approval for its anti-smoking drug, Chantix; Neurogen's insomnia drug, NG2-73, was effective in a Phase II study for insomnia; Gilead sold off a poor-selling cancer drug to Diatos for $4.7 million plus royalties; Gleevac from Novartis may inhibit bone formation, according to a small study; Prana Biotech will move its Alzheimer’s drug into Phase II tests; Targeted Genetics executed a 1-for-10 reverse split and changed its symbol; Biovest won approval to market AutovaxID, a device that produces cell-derived products for personalized medicine applications; and Alfacell presented new data on Onconase as a treatment for non-small cell lung cancer. The Centient Biotech 200™ was off by 32 points at 3704.72, a loss of .86%. More details...

Back to news